Author

N Joshi

Institution: AbbVie (United States)

Observed institution: AbbVie (United States)

OpenAlex ID: A5076725360

P434 Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn’s disease: Results from induction and maintenance phase 3 trials

2023 · S Ghosh, B Feagan, et al. · Journal of Crohn s and Colitis · 4

P786 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved clinical outcomes in patients with Crohn’s disease

2023 · J Panés, E Louis, et al. · Journal of Crohn s and Colitis · 1

P439 Induction of endoscopic response, remission and ulcer-free endoscopy with upadacitinib is associated with improved quality of life in patients with Crohn’s disease

2023 · J Panés, E Louis, et al. · Journal of Crohn s and Colitis · 1

Assoziation endoskopischer Ergebnisse mit langfristigen klinischen Verbesserungen bei Patienten mit mittelschwer bis schwer aktivem Morbus Crohn, die mit Upadacitinib behandelt wurden: Ergebnisse aus der U-ENDURE Langzeit-Erweiterungsstudie

2026 · E V Loftus, E Louis, et al. · Zeitschrift für Gastroenterologie

Analysis of long-term safety and efficacy of risankizumab in patients with moderate-to-severe Crohn’s Disease: 3-year results from the SEQUENCE study

2026 · L Peyrin-Biroulet, R Atreya, et al. · Zeitschrift für Gastroenterologie

P0784 Independent association between baseline simple endoscopic score for Crohn’s disease and C-reactive protein with Crohn’s disease-related complications: An analysis of the Randomized Evaluation of an Algorithm for Crohn’s Treatment – Study 2 (REACT2)

2025 · V Jairath, N Joshi, et al. · Journal of Crohn s and Colitis

P1040 Comparative effectiveness of upadacitinib versus ustekinumab in patients with moderately to severely active Crohn’s disease: a matching-adjusted indirect comparison

2024 · C Ma, M C Dubinsky, et al. · Journal of Crohn s and Colitis

Works count: 7

Citation count: 6

H-index: 1

I10-index: